In UK gynaecological services, AUB is the fourth most common referral cause. A study carried out by Frick and colleagues claimed losses of more than USD 2000 per patient per annum due to the absence of women from work. It has a significant impact on both economic and health care costs, directly affecting women and their families. From the gynaecological health perspective, menstrual disorders are the most prevalent gynaecological disorders in the United States around 30% women suffer from heavy menstrual bleeding (HMB) at some time during their reproductive years. In India, the reported prevalence of AUB is around 17.9% (National Health Portal, NPH)) and in UK, over 800,000 women seek help for AUB annually. The prevalence varies in each country (in the United States, United Kingdom and African countries, from 3–30%, with higher incidence occurring around menarche and perimenopause). AUB and heavy menstrual bleeding (HMB), a subgroup of AUB, are common conditions affecting 14–25% of women of reproductive age. Conclusions: The study concludes that both medroxyprogesterone acetate and ormeloxifene are safe and efficacious in controlling abnormal uterine bleeding, but ormeloxifene was the better of the two in terms of cost effectiveness, reduction in pictorial blood loss assessment score, endometrial thickness, bleeding duration (days), increase in haemoglobin concentration (g/dL) and improvement in the quality of life.Ībnormal uterine bleeding (AUB) is defined as bleeding from the uterine corpus that is abnormal in duration, frequency, volume and regularity. Health-related quality of life improved in the ormeloxifene group more than the medroxyprogesterone group, which was evidenced by SF-36 scale parameters (physical function, energy/fatigue and pain) that changed from 24.39, 12.99, 6.25 to 28.95, 18, 9 and from 25.41, 13.6, 7.1 to 27.02, 16, 8.3 in the ormeloxifene and medroxyprogesterone acetate groups, respectively. Similarly, mean haemoglobin increased from 8.56 ± 0.77 to 10.1 ± 0.087 g/dL and from 8.60 ☐.97 to 9.551 ± 0.90 g/dL ( p < 0.001), and endometrial thickness showed a reduction from 8.52 ± 1.61 mm to 6.92 ± 1.68 mm and from 8.40 ± 2.09 mm to 7.85 ± 2.0 mm ( p < 0.001) in the ormeloxifene and medroxyprogesterone acetate groups, respectively. Results: The mean duration of bleeding reduced from 16.88 ± 6.46 to 7.76 ± 1.55 in the ormeloxifene group and from 15.91 ± 5.04 to 8.7 ± 1.91 ( p < 0.001) in the medroxyprogesterone acetate. Cost-effectiveness was determined on the basis of the three-month treatment regimen. Health-related quality of life was assessed using short form survey-36 (SF-36) questionnaire scale. Patients were randomized into two groups for administering ormeloxifene and medroxyprogesterone acetate for a 3-month treatment duration and were evaluated by laboratorial investigations like anaemic status, bleeding duration, endometrial thickness, pictorial blood loss assessment chart (PBLAC) score, and patient’s medical and medication history. Materials and Methods: A prospective, randomized, single-blinded clinical trial of 367 patients was carried out at a tertiary care hospital for a period of one year from 5 January 2019 to 4 January 2020. The present study aims to compare the cost-effectiveness, safety, efficacy, and health-related quality of life of ormeloxifene with medroxyprogesterone acetate in women with non-structural abnormal uterine bleeding. Background and objectives: Abnormal uterine bleeding is a significant clinical and gynaecological concern that necessitates its safe and effective treatment.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |